During an address at the Vatican on 11 October 2026, Pope Leo XIV disclosed that medical staff had detected a nodule on his lung. The nodule's precise dimensions have not been established.

As of 12 October 2026, the condition had been identified at an early stage and remained confined to its original site, with no indication of spread to other tissue, though a fuller picture of its status had yet to enter the public record. Doctors advised the pontiff that the lung nodule would require surgical removal, with a recovery period of roughly one week anticipated following the procedure.

No public disclosure has been made about whether the lung finding arose without prior symptoms or whether the pope had already been experiencing health concerns when it was detected. A 2019 paper in the Annals of Thoracic Medicine described that distinction as an "increasingly common clinical dilemma" when nodules turn up in patients who had not reported any complaints.

Part of what makes that predicament difficult to resolve is that extracting a small tissue sample from a compact nodule — the standard method for determining whether cells are cancerous — poses real procedural challenges at that scale. Researchers publishing in the European Respiratory Review in 2017 determined that the procedural risks tied to surgically obtaining a tissue sample from small nodules tend to exceed any diagnostic gain, partly because cancerous findings in such nodules are relatively uncommon.

A trip covering Uruguay, Argentina, and Peru has been placed on the pope's calendar for the period running from 6 to 17 November.

Doctors typically describe a lung nodule as a small, rounded or irregularly shaped growth that appears as a pale mark on imaging of the lung tissue. On CT imaging, the brighter appearance of lung nodules against the darker backdrop of air-filled tissue is what prompts radiologists to use the term "opacity" when describing them.

Among the known triggers for lung nodules are prior respiratory infections, airborne particles that become trapped in lung tissue, inflammatory responses, the formation of scar tissue, and the possibility of early-stage cancer. When a nodule reaches beyond three centimetres in diameter, medical classification shifts it into the category of a mass.

Nodules measuring up to roughly 2 millimetres carry a low likelihood of malignancy, and that likelihood stays low through sizes approaching 6 to 7 millimetres. At a diameter of roughly 8 to 10 millimetres, that probability climbs into the 9 to 10 percent range. When a nodule exceeds one centimetre in diameter, the likelihood of that outcome stands at roughly 15 percent.

A 2026 review published in the New England Journal of Medicine found that subsolid nodules appear less often than solid ones on chest imaging, yet carry a greater probability of being cancerous — a detail the review noted given that lung nodules appear in roughly three out of every ten chest CT scans. Between 2008 and 2019, the proportion of scans flagging lung nodules climbed from roughly 38 per cent to around half, according to a Dutch research paper released in 2023. Between 2010 and 2017, the share of patients whose records showed newly identified nodules measuring at least 5 millimetres nearly doubled, climbing from 9 percent to 17 percent.

According to global health data, no other cancer type accounts for as many diagnoses or as many fatalities each year as lung cancer does. Figures released by the World Health Organization's International Agency for Research on Cancer put the number of new lung cancer cases across 2024 at close to 2.65 million, with fatalities from the condition surpassing 1.8 million over that same period.